The merger of automated LC fractionation & in-depth characterization
The presentation highlights the advancements and importance of cloud-based data management in the biopharmaceutical industry. Dr. Kristensen discusses how the shift from traditional data handling methods to cloud solutions has revolutionized their workflow, enabling access to vast amounts of data from anywhere, which is crucial given the exponential increase in data generation. He outlines the adoption of native mass spectrometry (MS) techniques since 2018, inspired by advancements seen at NIBA, leading to significant growth in data production.
The presentation emphasizes the robustness and reliability of their MS platforms, particularly SEC MS, which has proven effective across multiple instrument generations. Dr. Kristensen underscores the importance of centralized data and metadata retrievability for efficient and accurate analysis. The talk concludes with appreciation for collaborative efforts and the critical role of innovative technologies in driving impactful scientific advancements in oncology and other therapeutic areas.
Learning points
- Cloud-Based Data Management: The transition to cloud-based solutions is essential for handling the exponential increase in data generation.
- Advancements in Mass Spectrometry: The adoption of new mass spectrometry (MS) techniques, such as native MS and SEC MS, has significantly improved the robustness and reliability of analytical platforms.
- Impact of Modifications on Therapeutic Efficacy and Safety: The importance of understanding how various modifications, such as glycation and deamidation, impact the safety and efficacy of biopharmaceutical products.
Who should attend?
- Researchers and Scientists: Those working in glycomics, proteomics, and related fields who are interested in the latest advancements and methodologies.
- Biotechnology and Pharmaceutical Professionals: Professionals involved in the development and commercialization of therapeutics who are looking for ways to accelerate their processes and enhance innovation.
- Academic and Training Institutions: Institutions focused on bioprocessing research and training that can leverage new technologies and approaches to enhance their programs and facilities.
Presenter: Dr. Dan Bach Kristensen (Principal Scientist, Symphogen)
Dan Bach Kristensen holds a Ph.D. in Biology and a Bachelor of Science in Chemistry. Dan is specialized in protein chemistry and mass spectrometry (MS), for which he initially applied in the field of proteome research in Japan and then later in Denmark. For the past 15 years, Dan has been working with analytical development in the biopharmaceutical industry on projects ranging from early discovery through to product registration. Clinical indications include bleeding disorders, neutropenia, autoimmune diseases, and oncology. Dan currently works as a principal scientist at Symphogen, which is specialized in the development of antibodies and antibody mixtures for the treatment of cancer.
